Healthcare Professional Market Research in Singapore: Getting Doctors to Tell You What They Actually Think
The Real Problem with Healthcare Professional Research in Singapore
Pharmaceutical companies commission expensive HCP studies. Across our 600+ research projects, healthcare professional research consistently surfaces the widest gap between reported and actual opinion. Data comes back tidy. Strategic implications remain unclear. This is the real problem with HCP research in Singapore: doctors are trained to be diplomatic and aware of commercial agendas. They give responses that satisfy without committing. Getting authentic perspectives requires understanding stated versus actual views.
Singapore has approximately 15,000 registered medical practitioners serving a population of 5.9 million. WHO country data for Singapore provides additional context on how this physician density compares regionally. This small, concentrated professional community shapes how HCPs engage with research. When everyone knows everyone (or someone who knows), caution becomes strategy.
Four Layers That Distort HCP Research Responses
The Small World Effect
Singapore's medical community is small. Under frameworks like MOH's Healthcare Services Act, HCPs are cautious about expressing views. The HSA therapeutic products register adds a further layer: clinicians who participate in product-related research know their opinions may influence regulatory perception. They are cautious about expressing views that might circulate back to colleagues or hospital leadership. In research settings, this manifests as careful hedging. Opinions are attributed to unnamed others rather than owned personally. It's professional survival in a concentrated market.
The Pharma-Aware Filter
Singapore HCPs have developed sophisticated filters for commercial engagement. When they recognize research as pharma-sponsored, responses calibrate accordingly. Some provide artificially positive feedback, while others become artificially skeptical. Neither represents authentic clinical judgment.
The Institutional Loyalty Layer
Many Singapore HCPs work within the public healthcare system. Institutional affiliation shapes how they discuss treatment options. The Straits Times health reporting frequently highlights how this institutional pressure shapes what Singapore doctors say publicly about treatment approaches. A doctor at a hospital that championed Drug A will find it professionally awkward to express preference for Drug B. The constraint is real. The impact on research validity is overlooked.
The KOL Phenomenon
Key Opinion Leaders shape treatment consensus. Other HCPs often echo KOL positions because deviation feels professionally risky. Research that captures KOL views mistakes it for consensus. I've seen advisory boards where 80% of responses aligned with published KOL positions. It looked like consensus. It was conformity.
What HCPs Say vs. What They Mean
Physicians often express themselves diplomatically. "It depends on the patient" frequently means they don't want to commit to a position. "The data looks promising" may indicate politeness masking reservations. "We follow institutional guidelines" suggests personal views may differ. Understanding these patterns requires case-based probing (our research guide covers this technique in depth): "Walk me through your last three cases where this came up." This reveals actual practice rather than stated preferences.
What should pharmaceutical companies ask before commissioning HCP research in Singapore?
Is your advisory board giving you authentic insight or sophisticated consensus?
Are you confusing KOL agreement with broader clinical consensus?
How can researchers engage busy healthcare specialists without compromising data quality?
What regulatory and ethical considerations shape HCP research in Singapore?
How do you identify and engage Key Opinion Leaders without biasing the sample?
Designing HCP Research That Actually Works
What separates high-quality HCP research from misleading studies? It's not methodology alone. It's accounting for the professional and cultural filters that shape physician responses. Standard research approaches produce standard (and often misleading) data because they ignore these filters.
Moderators with clinical credibility matter more than generic market researchers. Case-based discussions ("walk me through a recent patient") reveal actual behavior better than abstract hypotheticals. Credible, specific anonymity assurances (not boilerplate confidentiality) enable honesty. For research involving experimental treatments, understanding HSA's clinical trial frameworks helps design studies that comply with regulatory requirements. Individual interviews for sensitive topics, not group discussions where hierarchy creates pressure. Third-party research branding increases candor. Mixing HCPs from different institutions prevents single-hospital perspective dominance.
These design choices aren't nice-to-haves. They're essential for reaching the 15-20% of HCPs who will actually tell you the truth. The other 80% will tell you what's safe.
Understanding what your doctors actually think, not what they tell your reps
Healthcare professional research requires behavioural probing beyond satisfaction surveys. We recruit HCPs who practise in your therapeutic area and design studies that capture genuine clinical decision-making.
Request a quote →
